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The Journal of Investigative Dermatology has served suc-
cessfully as the most prominent international organ of
cutaneous science and cutaneous pathology since its in-
ception in 1938. Although established and owned by the
Society for Investigative Dermatology (SID), its North Amer-
ican emphasis was expanded in 1990, when the European
Society for Dermatological Research joined the SID in
sponsorship. During 66 years of life, there have been sev-
eral changes in emphasis, each reflecting transitions in em-
phasis among the various scientific communities that it
represents. In the first half of its life, clinical observation was
gradually replaced by experimentation. Reading issues from
the 1970s reveals substantial emphasis on laboratory in-
vestigation, as was required by the cutaneous scientists
who laid the foundation of modern scientific dermatology.
Of course, this was aided by knowledge that competition
among the specialties for national and international funding
required excellence in the laboratory. Over the last two
decades, one can observe continued interest in biochem-
istry and physiology, but at the same time a growing interest
in genetics and bioinformatics. An astounding array of
genetic characterizations and identifications have been
reported, however primarily for single gene ‘‘defects.’’
Over the last several years, I have had the opportunity to
make ‘‘In This Issue’’ comments during the winter of each
year, beginning during the tenure of Editor Conrad Hauser.
During this time, I have been struck by the growing em-
phasis in this Journal on clinical investigation and clinical
science, a trend initiated by Dr Hauser. At the same time, I
have been struck by the observation that increasingly, the
best studies require highly refined and well-described pa-
tient populations. For example:
Winter and colleagues identified a single nucleotide po-
lymorphism that was ‘‘required’’ for the expression of
pseudofolliculitis barbae in African-American men (Winter
et al, 2004). Their discovery began with access to a well-
defined population of American Servicemen in Germany.
Alamartine and colleagues reported that IL-10 promoter
polymorphisms conferred susceptability to cutaneous
squamous cell carcinomas in recipients of renal trans-
plants (Alamartine et al, 2003). This discovery required ac-
cess to a well-defined cohort of renal transplant patients.
Warren and colleagues reported that autoantibodies to
desmoglein-1 of the IgG4 subclass alone were required
for the expression of endemic pemphigus foliaceus
(Warren et al, 2003). Access to multiple sera samples
from patients and control subjects in a unique region of
the world was required for this work.
These papers and many others over the last ten years
demonstrate a trend that requires cohorts of patients to be
involved directly in the cutting-edge studies that are now
reported in the Journal. It is not to say that biochemistry
and physiology and single-patient studies have been aban-
doned; rather, this has been a process of supplementation.
And now it is the year 2005. Found within the Journal this
month is an excellent example of this continuing transition
‘‘back’’ to clinical science. Palmer, Hawk, Young, and Walk-
er (2005) studied the effect of solar-simulated radiation on
elicitation phases of contact sensitivity (contact allergic
dermatitis). The critical element, once again, was the es-
tablishment of a well-defined clinical population that al-
lowed observations to be made. These investigators tested
the hypothesis that patients with polymorphic light eruption
are resistant to the expected suppression of contact sen-
sitivity elicitation reactions by ultraviolet radiation (UVR).
Importantly, their hypothesis arose from the earlier obser-
vation that patients with this disease were resistant to the
UVR-induced suppression that occurs normally during sen-
sitization. Working with the contact sensitizer dinitrochloro-
benzene, the experiments and the observations these
investigators report are clear: the hypothesis cannot be
sustained. In the vernacular, it is a ‘‘negative study.’’
So, what does this tell us? (1) To begin, what is true about
immunological sensitization is not true of elicitation. This
work compliments contemporary work in experimental an-
imals that there are substantial immunological differences in
the regulation of sensitization and regulation of elicitation. (2)
We, the readers and the authors, may want to celebrate an
Editor and Deputy Editors who have the wisdom to know that
‘‘negative’’ data may be just as illuminating as that which is
‘‘positive.’’ And (3) we may celebrate a Journal that continues
to lead back to a comfortable marriage between basic and
clinical science. After all, it all has to do with Health.
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